TNYA Graph | Tenaya Therapeutics, Inc.

TNYA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $1.11M; Research and development $16.60M; Operating expenses $45.20M; Income tax $0.00.
2026-03-31: Revenue $225.00K; Research and development $14.84M; Operating expenses $20.29M; Income tax $0.00.
2025-12-31: Revenue (m); Research and development $14.80M*; Operating expenses $20.77M*; Income tax $0.00*.
2025-09-30: Revenue (m); Research and development $15.36M; Operating expenses $20.94M; Income tax (m).

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$1.11M	$16.60M	$45.20M	$0.00	-$43.39M
2026-03-31	$225.00K	$14.84M	$20.29M	$0.00	-$19.27M
2025-12-31	(m)	$14.80M*	$20.77M*	$0.00*	-$20.18M*
2025-09-30	(m)	$15.36M	$20.94M	(m)	-$20.27M
2025-06-30	$0.00	$17.37M	$24.08M	$0.00	-$23.28M
2025-03-31	$0.00	$21.08M	$27.54M	$0.00	-$26.86M
2024-09-30	(m)	$20.35M	$26.71M	(m)	-$25.63M
2024-06-30	(m)	$22.65M	$30.82M	(m)	-$29.43M
2024-03-31	(m)	$25.05M	$33.76M	$0.00	-$32.23M
2023-09-30	(m)	$23.09M	$30.92M	(m)	-$29.14M
2023-06-30	(m)	$26.48M	$35.10M	(m)	-$33.27M
2023-03-31	(m)	$25.61M	$33.72M	$0.00	-$31.74M
2022-09-30	(m)	$23.76M	$31.30M	(m)	-$30.70M
2022-06-30	(m)	$20.88M	$28.62M	(m)	-$28.40M
2022-03-31	(m)	$24.16M	$31.15M	$0.00	-$31.06M
2021-09-30	(m)	$12.94M	$18.30M	$0.00	-$18.26M
2021-06-30	(m)	$10.91M	$15.24M	$0.00	-$15.21M
2021-03-31	(m)	$9.59M	$13.11M	$0.00	-$13.10M
2020-09-30	(m)	$8.48M	$10.45M	$0.00	-$10.29M
2020-06-30	(m)	$6.96M	$8.87M	$0.00	-$8.73M
2020-03-31	(m)	(m)	(m)	(m)	-$9.05M

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$1.33M	$31.45M	$65.49M	$0.00	-$62.66M
2025-06-30	$0.00	$38.45M	$51.62M	$0.00	-$50.15M
2024-06-30	(m)	$47.70M	$64.58M	$0.00	-$61.66M
2023-06-30	(m)	$52.08M	$68.83M	$0.00	-$65.01M
2022-06-30	(m)	$45.03M	$59.77M	$0.00	-$59.45M
2021-06-30	(m)	$20.50M	$28.34M	$0.00	-$28.31M
2020-06-30	(m)	$14.26M	$18.14M	$0.00	-$17.78M

Revenue and expense 9 month

Period end	Research and development	Operating expenses	Income tax	Net income
2025-09-30	$53.81M	$72.56M	$0.00	-$70.42M
2024-09-30	$68.05M	$91.30M	$0.00	-$87.29M
2023-09-30	$75.17M	$99.75M	$0.00	-$94.15M
2022-09-30	$68.79M	$91.07M	$0.00	-$90.15M
2021-09-30	$33.44M	$46.64M	$0.00	-$46.57M
2020-09-30	$22.73M	$28.59M	$0.00	-$28.08M

Revenue and expense 12 month

Period end	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$68.61M	$93.33M	$0.00	-$90.60M
2024-12-31	$86.74M	$115.95M	$0.00	-$111.13M
2023-12-31	$98.04M	$131.19M	$0.00	-$124.08M
2022-12-31	$94.54M	$125.62M	$0.00	-$123.67M
2021-12-31	$54.39M	$72.81M	$0.00	-$72.72M
2020-12-31	$31.10M	$38.91M	$0.00	-$38.40M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Caribou Biosciences, Inc. (CRBU)	United States	$0.134B	-1.79
Armata Pharmaceuticals, Inc. (ARMP)	United States	$0.132B
Neumora Therapeutics, Inc. (NMRA)	United States	$0.132B	-1.48
enGene Therapeutics Inc. (ENGN)		$0.129B	-0.92
Humacyte, Inc. (HUMA)	United States	$0.155B	-2.26
Outlook Therapeutics, Inc. (OTLK)	United States	$0.162B	-4.90
Acumen Pharmaceuticals, Inc. (ABOS)	United States	$0.162B	-1.83
LENZ Therapeutics, Inc. (LENZ)	United States	$0.117B	-1.41
Black Diamond Therapeutics, Inc. (BDTX)	United States	$0.109B	-2.48
Voyager Therapeutics, Inc. (VYGR)	United States	$0.173B	-1.99